Dosage Forms

Articles

The acquisition will add recombinant-based influenza vaccine to Sanofi Pasteur’s portfolio

Sanofi Acquires Protein Sciences

The directorate highlights its 2016 achievements.

EDQM Releases Annual Report

Two recently-signed agreements will transfer Takeda’s measles and acellular pertussis vaccine technologies to India-based multinational company Biological E. Limited to develop low-cost combination vaccines including diphtheria, tetanus and acellular pertussis (DTaP), and measles-rubella (MR) vaccines.

Biological E Licenses Combination Vaccine Development from Takeda

A loan from the European Investment Bank will give BiondVax resources for Phase III trials and a manufacturing facility for its universal flu vaccine.


BiondVax Receives European Union Investment in Universal Flu Vaccine Development

The agency issued its recommendation for the influenza virus strains European vaccine manufacturers should include for 2017.

EMA Updates Flu Vaccination Recommendations

In a new study, researchers from Boston Children’s Hospital study responses to pneumococcal vaccine in infant monkeys.

Researchers Study Vaccine Responses in Newborns

Randi Hernandez was science editor at Pharmaceutical Technology from September 2014 to May 2017.

The partnership will focus on providing practical information to clients on the development of biologics and vaccines.

CSSi LifeSciences and BioMARC Partner to Accelerate Biologics Manufacture

Univercells received a grant from the Bill & Melinda Gates Foundation for the development of a vaccine manufacturing platform.

Univercells Receives $12-Million Grant to Develop Vaccine Manufacturing Platform

GlaxoSmithKline opened a new vaccines R&D center in Rockville, MD creating up to 200 new jobs.

GSK Opens Global Vaccines R&D Center in Maryland

Takeda will invest more than 100 million Euros to build a new manufacturing plant for its dengue vaccine candidate in Singen, Germany.